CPX in Paradoxical Low Flow Aortic Stenosis

Sponsor
Henry Ford Health System (Other)
Overall Status
Withdrawn
CT.gov ID
NCT05481814
Collaborator
(none)
0
1
57
0

Study Details

Study Description

Brief Summary

Severe aortic stenosis is a condition with poor life expectancy once it becomes symptomatic. There are no prospective studies illustrating the utility of cardiopulmonary stress (CPX) testing in diagnosing and prognosticating patients with paradoxically low gradient and low flow severe aortic stenosis. We aim to prospectively investigate the utility of CPX in this patient population with the hypothesis that utilizing CPX parameters would better identify higher risk patients warranting further evaluation and possibly intervention sooner.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This will be a prospective crossectional, longitudinal study recruiting patients by invitation with paradoxical low flow low gradient severe aortic stenosis. Patients with PLFLG AS will have been identified in other studies and these patients will be approached for enrollment in the study. Patients deemed appropriate for enrollment will undergo recumbent bicycle stress testing with concomitant measure of gas exchange. The bicycle will be at 30 degrees with initiation of minimal resistance for 3 minutes, followed by an increase in work-rate of 25 watts every two minutes until the patient reaches a sign/symptom-limited maximum exertion or test limiting symptoms develop. Charts will be reviewed for baseline medical conditions and demographics. CPX protocol will be standard HFH protocol supervised by exercise physiologist. The first phase of the study will be investigating if these asymptomatic patients will be reclassified to symptomatic as defined by reduced V02 Max. The second phase will be following these patients for long term adverse events and if V02 max correlates with a higher risk.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    0 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Role of Cardiopulmonary Stress Testing in Diagnostic Evaluation of Paradoxical Low Gradient Aortic Valve Stenosis
    Anticipated Study Start Date :
    Sep 30, 2017
    Anticipated Primary Completion Date :
    Apr 1, 2018
    Actual Study Completion Date :
    Jul 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Functional status [August 30 2017-April 30 2017]

      Evaluate changes in rest vs. Peak V02 at maximal exercise capacity.

    Secondary Outcome Measures

    1. Follow-up [August 30 2017- August 30 2019]

      Follow patients long term for major adverse cardiac events including myocardial infarction, stroke, hospitalization, or death and if CPX parameters provide further prognostic information in this patient population

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Aortic valve area <1 cm2

    • Mean aortic pressure gradient <40 mmHg,

    • Left ventricular ejection fraction >50% by 2D transthoracic echocardiography

    Exclusion Criteria:
    • Ischemic heart disease

    • Severe mitral valve disease (regurgitation or stenosis)

    • Moderate or severe aortic regurgitation

    • Pulmonary hypertension (PA pressure >50 mmHg)

    • COPD

    • Uncontrolled hypertension (Systolic BP or Diastolic BP greater than 150/90)

    • Inability or unwillingness to exercise.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Henry Ford Hospital Detroit Michigan United States 48202

    Sponsors and Collaborators

    • Henry Ford Health System

    Investigators

    • Principal Investigator: Karthikeyan Ananthasubramaniam, MD, Henry Ford Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Karthikeyan Ananthasubramaniam, Senior Staff Cardiologist, Henry Ford Health System
    ClinicalTrials.gov Identifier:
    NCT05481814
    Other Study ID Numbers:
    • PLFLGAS1
    First Posted:
    Aug 1, 2022
    Last Update Posted:
    Aug 1, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 1, 2022